The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pneumococcal Vaccine Market Research Report 2024
Synopsis
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
The global Pneumococcal Vaccine market was valued at US$ 7200.2 million in 2023 and is anticipated to reach US$ 7780.4 million by 2030, witnessing a CAGR of 1.1% during the forecast period 2024-2030.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
This report aims to provide a comprehensive presentation of the global market for Pneumococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pneumococcal Vaccine.
Report Scope
The Pneumococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pneumococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by End User, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pneumococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by End User, and by regions.
Market Segmentation
By Company
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Segment by Type
PPSV 23
PCV 7/13
PCV 10
Segment by End User
Child
Adult
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by End User, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pneumococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by End User, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
The global Pneumococcal Vaccine market was valued at US$ 7200.2 million in 2023 and is anticipated to reach US$ 7780.4 million by 2030, witnessing a CAGR of 1.1% during the forecast period 2024-2030.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
This report aims to provide a comprehensive presentation of the global market for Pneumococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pneumococcal Vaccine.
Report Scope
The Pneumococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pneumococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by End User, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pneumococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by End User, and by regions.
Market Segmentation
By Company
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Segment by Type
PPSV 23
PCV 7/13
PCV 10
Segment by End User
Child
Adult
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by End User, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pneumococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by End User, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pneumococcal Vaccine Market Overview
1.1 Product Overview and Scope of Pneumococcal Vaccine
1.2 Pneumococcal Vaccine Segment by Type
1.2.1 Global Pneumococcal Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 PPSV 23
1.2.3 PCV 7/13
1.2.4 PCV 10
1.3 Pneumococcal Vaccine Segment by End User
1.3.1 Global Pneumococcal Vaccine Market Value by End User: (2024-2030)
1.3.2 Child
1.3.3 Adult
1.4 Global Pneumococcal Vaccine Market Size Estimates and Forecasts
1.4.1 Global Pneumococcal Vaccine Revenue 2019-2030
1.4.2 Global Pneumococcal Vaccine Sales 2019-2030
1.4.3 Global Pneumococcal Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pneumococcal Vaccine Market Competition by Manufacturers
2.1 Global Pneumococcal Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pneumococcal Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pneumococcal Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Pneumococcal Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pneumococcal Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pneumococcal Vaccine, Product Type & Application
2.7 Pneumococcal Vaccine Market Competitive Situation and Trends
2.7.1 Pneumococcal Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pneumococcal Vaccine Players Market Share by Revenue
2.7.3 Global Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pneumococcal Vaccine Retrospective Market Scenario by Region
3.1 Global Pneumococcal Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pneumococcal Vaccine Global Pneumococcal Vaccine Sales by Region: 2019-2030
3.2.1 Global Pneumococcal Vaccine Sales by Region: 2019-2024
3.2.2 Global Pneumococcal Vaccine Sales by Region: 2025-2030
3.3 Global Pneumococcal Vaccine Global Pneumococcal Vaccine Revenue by Region: 2019-2030
3.3.1 Global Pneumococcal Vaccine Revenue by Region: 2019-2024
3.3.2 Global Pneumococcal Vaccine Revenue by Region: 2025-2030
3.4 North America Pneumococcal Vaccine Market Facts & Figures by Country
3.4.1 North America Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pneumococcal Vaccine Sales by Country (2019-2030)
3.4.3 North America Pneumococcal Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pneumococcal Vaccine Market Facts & Figures by Country
3.5.1 Europe Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pneumococcal Vaccine Sales by Country (2019-2030)
3.5.3 Europe Pneumococcal Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pneumococcal Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pneumococcal Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Pneumococcal Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pneumococcal Vaccine Market Facts & Figures by Country
3.7.1 Latin America Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pneumococcal Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Pneumococcal Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pneumococcal Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Pneumococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pneumococcal Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pneumococcal Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pneumococcal Vaccine Sales by Type (2019-2030)
4.1.1 Global Pneumococcal Vaccine Sales by Type (2019-2024)
4.1.2 Global Pneumococcal Vaccine Sales by Type (2025-2030)
4.1.3 Global Pneumococcal Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Pneumococcal Vaccine Revenue by Type (2019-2030)
4.2.1 Global Pneumococcal Vaccine Revenue by Type (2019-2024)
4.2.2 Global Pneumococcal Vaccine Revenue by Type (2025-2030)
4.2.3 Global Pneumococcal Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Pneumococcal Vaccine Price by Type (2019-2030)
5 Segment by End User
5.1 Global Pneumococcal Vaccine Sales by End User (2019-2030)
5.1.1 Global Pneumococcal Vaccine Sales by End User (2019-2024)
5.1.2 Global Pneumococcal Vaccine Sales by End User (2025-2030)
5.1.3 Global Pneumococcal Vaccine Sales Market Share by End User (2019-2030)
5.2 Global Pneumococcal Vaccine Revenue by End User (2019-2030)
5.2.1 Global Pneumococcal Vaccine Revenue by End User (2019-2024)
5.2.2 Global Pneumococcal Vaccine Revenue by End User (2025-2030)
5.2.3 Global Pneumococcal Vaccine Revenue Market Share by End User (2019-2030)
5.3 Global Pneumococcal Vaccine Price by End User (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Pneumococcal Vaccine Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Pneumococcal Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 MSD
6.3.1 MSD Corporation Information
6.3.2 MSD Description and Business Overview
6.3.3 MSD Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 MSD Pneumococcal Vaccine Product Portfolio
6.3.5 MSD Recent Developments/Updates
6.4 Sanofipasteur
6.4.1 Sanofipasteur Corporation Information
6.4.2 Sanofipasteur Description and Business Overview
6.4.3 Sanofipasteur Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofipasteur Pneumococcal Vaccine Product Portfolio
6.4.5 Sanofipasteur Recent Developments/Updates
6.5 CDIBP
6.5.1 CDIBP Corporation Information
6.5.2 CDIBP Description and Business Overview
6.5.3 CDIBP Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CDIBP Pneumococcal Vaccine Product Portfolio
6.5.5 CDIBP Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pneumococcal Vaccine Industry Chain Analysis
7.2 Pneumococcal Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pneumococcal Vaccine Production Mode & Process
7.4 Pneumococcal Vaccine Sales and Marketing
7.4.1 Pneumococcal Vaccine Sales Channels
7.4.2 Pneumococcal Vaccine Distributors
7.5 Pneumococcal Vaccine Customers
8 Pneumococcal Vaccine Market Dynamics
8.1 Pneumococcal Vaccine Industry Trends
8.2 Pneumococcal Vaccine Market Drivers
8.3 Pneumococcal Vaccine Market Challenges
8.4 Pneumococcal Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
